Aug 8, 2023Meissa's Positive Clinical Data for the First RSV Vaccine Designed to Protect Infants & Toddlers
Jun 28, 2023Meissa Vaccines Enters into CGMP Manufacturing Agreement for Pediatric RSV Vaccine Candidate
Nov 7, 2022Meissa's Positive Interim Clinical Data for Its Intranasal Live Attenuated RSV Vaccine for Infants
Oct 28, 2021Meissa Announces Positive Preliminary Clinical Data on Safety and Immunogenicity of Intranasal COVID
Jul 19, 2021Preclinical Data on Intranasal COVID-19 Vaccine Shows Protection from SARS-CoV-2 after Single Dose
Mar 16, 2021Meissa Announces IND Clearance for Phase 1 Study of COVID-19 Intranasal Live Attenuated Vaccine
Jan 21, 2021Meissa Announces 1st Dosing in Phase 2 Study of Intranasal Live Attenuated Vaccine Candidate for RSV
Oct 13, 2020Meissa Vaccines Expands Leadership Team as Company Advances Intranasal RSV and COVID-19 Candidates
Jan 10, 2020Meissa Vaccines Receives U.S. FDA Fast Track Designation for Respiratory Syncytial Virus Vaccine
Jul 11, 2017Meissa Vaccines Awarded NIH SBIR Grant to Advance IND Preparations for RSV Vaccine Candidate
Jul 11, 2017Meissa Vaccines Receives FDA Clearance of IND Application, Phase 1 Clinical Trial of MV-012-968
May 10, 2017Meissa Awarded NIH SBIR Grant to Support Development of Multivalent Human Rhinovirus Vaccine Candida
